Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Endometriosis-Associated Pain: A Systematic Review and Meta-Analysis.
To evaluate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists versus placebo for treatment of endometriosis-associated pain and to compare individual antagonists indirectly for dysmenorrhea and non-menstrual pelvic pain.
Analgesic and Anti-Inflammatory Activity of Ambroxol in the Treatment of Endometriosis: An Experimental Study in Wistar Rats.
Background/Objective: This study evaluated the analgesic and anti-inflammatory effects of ambroxol in an experimental model of endometriosis. Methods: Ambroxol was administered at doses of 10, 50, and 100 mg/kg (Abx …
BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - BioPharm International
BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer BioPharm International
The efficacy of ultrasound-guided treatment of ovarian endometriosis cysts: A meta-analysis.
The purpose of this meta-analysis was to systematically assess the efficacy of ultrasound-guided therapy of ovarian endometriosis cyst (OEC). Several databases were searched to gather published studies on the efficacy …
Social Media Health Information Formats and Endometriosis Treatment-Seeking Intentions: A Randomized Controlled Trial.
BackgroundDespite many women learning about endometriosis on social media, posts about the condition often fail to reflect current evidence. With the content and credibility of online health messages being found …
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times